Cytori Rises on Crucial FDA Approval
Cytori Therapeutics saw its shares explode after it was reported that the firm received approval from the FDA for its treatment of thermal burn injuries.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 172
OncoMed Hits All-Time Low After Failed Trial and Licensing Fallout
OncoMed Pharmaceuticals saw its shares crumble after the company announced that Bayer Pharma is terminating its option agreement with the company as well as a missed mid-stage trial.
Jefferies Thinks 3 Red-Hot Biotech Stocks Can Beat Q1 Estimates
A massive new Jefferies research report reminds investors that as a rule the first quarter is traditionally slower for biotechnology stocks.
Biohaven Files for IPO
Biohaven Pharmaceutical has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Catalyst Biosciences Sinks After Pricing Secondary Offering
Catalyst Biosciences watched its shares fall on Friday following the announcement of a secondary offering.
Aurinia Pharmaceuticals Jumps on Phase 3 Planned Trial
Shares of Aurinia Pharmaceuticals saw a handy gain on Friday after the company announced plans for the development of a late-stage trial.
Neothetics Posts Solid Win on Patent Approval
Neothetics saw its stock hit a multiyear high on Wednesday after the firm announced a critical patent approval.
Is This the Turnaround Paratek Has Been Looking For?
Shares of Paratek Pharmaceuticals saw a huge gain early on Tuesday after the company provided a critical update on its late-stage pneumonia trial.
Fresh Off IPO, Therapix Biosciences Already Aiming at Tourette’s Phase 3 Trial
The road to a pivotal Phase 3 trial usually takes years following an IPO, but Therapix Biosciences may reach that stage in just a few months' time.
Why One Analyst Sees Almost 40% Upside in Integra LifeSciences
Argus likes Integra’s strong growth prospects and its ability to execute on acquisition and mergers that help move the company's needle on growth in revenue and earnings.
Tocagen Announces Potential Pricing for IPO
Tocagen expects to price more than 7 million shares in the range of $10 to $12 apiece for an initial public offering valued up to about $100 million.
Why NovoCure Shares Are Skyrocketing
NovoCure saw its shares skyrocket early on Monday after the firm provided an update for its late-stage cancer trial.
Cara Therapeutics Announces Pricing for Secondary Offering
Cara Therapeutics has priced more than 4 million shares of common stock at $18 per share in a secondary offering valued up to around $92 million.
How Akari Therapeutics Is Putting Itself on the Map
Shares of Akari Therapeutics saw a handy gain on Friday after the firm announced that the FDA granted a Fast Track designation for its treatment of paroxysmal nocturnal hemoglobinuria.
Why This Key Analyst Has a Mixed View of Vertex’s Win
Vertex Pharmaceuticals shares were jumping after the firm released results from two Phase 3 studies in the treatment of cystic fibrosis in ages 12 and older.